| Quarterly Financials | Mar 2025 | Jun 2025 |
Revenue  | 165 | 119 |
| Expenses | 150 | 103 |
| EBITDA | 15 | 17 |
| Operating Profit % | 9 % | 14 % |
| Depreciation | 2 | 1 |
| Interest | 8 | 7 |
| Profit Before Tax | 7 | 9 |
| Tax | 1 | 2 |
| Net Profit | 6 | 7 |
| EPS in ₹ | 12.71 | 14.33 |
Fredun Pharmaceuticals
Fredun Pharmaceuticals
1,564.00
+15.70
(1.01%)
Key Fundamentals
Market Cap
732.50 Cr
EPS
44.83
PE Ratio
37.10
Dividend Yield
0.05 %
Industry
Healthcare 52 Week High
1,785.00
52 Week Low
635.00
PB Ratio
5.18
Debt to Equity
0.88
Sector
Pharmaceuticals Actual
Company News
View All News
Parag Goyal has resigned from his position as Company Secretary and Compliance Officer of Fredun Pharmaceuticals Limited, effective from the close of working hours on November 26, 2025. The resignation was attributed to personal commitments and has been accepted by the Board. Goyal expressed gratitude for the opportunity to serve the company and the support received during his tenure. The company will inform stock exchanges once a new Company Secretary and Compliance Officer is appointed.
Fredun Pharmaceuticals Limited reported a net profit of Rs 9.73 crore for the quarter ended September 30, 2025, compared to Rs 4.27 crore in the same quarter last year, marking a 128% increase. Revenue from operations rose to Rs 149.59 crore from Rs 102.99 crore year-on-year. For the half-year period, net profit increased to Rs 16.50 crore from Rs 8.40 crore previously. The company's earnings per share improved to Rs 20.61 from Rs 9.05 in the corresponding quarter. The Board of Directors approved these unaudited financial results at their meeting held on November 8, 2025. The company operates in the pharmaceutical and healthcare segment with manufacturing facilities in Palghar, Maharashtra.
Fredun Pharmaceuticals Launches India's First Pure Jain Dog Biscuit 'Snacky Jain'Oct 13, 2025
Fredun Pharmaceuticals has launched 'Snacky Jain', marketed as India's first pure Jain dog biscuit. The product is formulated without root vegetables or animal ingredients, adhering to Jain dietary principles. The company is initiating sales across six cities and has announced plans for expansion.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,691.40 | #1 4,05,823.50 | 38.74 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 55.98 | |
6,656.50 | 1,76,709.20 | 71.11 | 9,712.00 | 18.67 | 2,191 | 35.10 | 58.39 | |
1,505.70 | 1,21,623.50 | 22.36 | 28,409.50 | 7.12 | 5,291 | 3.71 | 40.84 | |
3,580.00 | 1,21,163.50 | 60.51 | 11,539.40 | 6.99 | 1,911 | 30.46 | 50.54 | |
1,205.40 | 1,00,604.30 | #1 17.53 | 33,741.20 | 16.73 | 5,725 | -0.38 | 37.06 | |
944.10 | 94,998.60 | 18.88 | 23,511.00 | 18.55 | 4,615 | 34.60 | 33.87 | |
2,261.80 | 93,357.70 | 52.66 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 25.15 | |
1,971.80 | 90,062.90 | 20.71 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 53.33 | |
5,668.50 | 67,775.40 | 29.08 | 13,458.30 | 3.70 | 2,216 | 21.39 | 63.91 | |
1,123.80 | 65,270.50 | 19.24 | 32,345.60 | 9.43 | 3,484 | 3.81 | 53.78 |
Growth Rate
Revenue Growth
26.26 %
Net Income Growth
44.44 %
Cash Flow Change
96.95 %
ROE
14.72 %
ROCE
9.48 %
EBITDA Margin (Avg.)
4.01 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 23 | 43 | 56 | 79 | 105 | 141 | 162 | 187 | 257 | 308 | 487 |
| Fixed Assets | 8 | 15 | 16 | 16 | 31 | 31 | 30 | 32 | 39 | 47 | 53 |
| Current Assets | 13 | 28 | 35 | 52 | 73 | 109 | 130 | 153 | 216 | 257 | 428 |
| Capital Work in Progress | 1 | 0 | 4 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 240 |
| Other Assets | 14 | 29 | 36 | 52 | 74 | 110 | 131 | 155 | 218 | 260 | 0 |
| Total Liabilities | 23 | 43 | 56 | 79 | 105 | 141 | 162 | 187 | 257 | 308 | 487 |
| Current Liabilities | 16 | 32 | 41 | 43 | 53 | 86 | 87 | 74 | 140 | 167 | 327 |
| Non Current Liabilities | 4 | 7 | 8 | 14 | 13 | 14 | 32 | 45 | 21 | 19 | 18 |
| Total Equity | 3 | 4 | 7 | 22 | 39 | 41 | 43 | 68 | 96 | 122 | 141 |
| Reserve & Surplus | 1 | 1 | 2 | 19 | 35 | 37 | 39 | 63 | 84 | 115 | 137 |
| Share Capital | 3 | 3 | 5 | 3 | 4 | 4 | 4 | 4 | 5 | 5 | 5 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 0 | 1 | -1 | 1 | 0 | 2 | -2 | 1 | 1 | -2 |
| Investing Activities | -3 | -6 | -7 | -8 | -5 | -2 | -1 | -4 | -9 | -8 |
| Operating Activities | 2 | 3 | 4 | 17 | 1 | -11 | 0 | -2 | -14 | -0 |
| Financing Activities | 1 | 4 | 3 | -8 | 4 | 14 | -1 | 8 | 25 | 6 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Nov 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | May 2023 | Jun 2023 | Aug 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Apr 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 52.04 % | 52.04 % | 52.04 % | 51.27 % | 51.27 % | 51.27 % | 51.04 % | 51.04 % | 50.34 % | 50.15 % | 49.62 % | 49.62 % | 49.33 % | 49.31 % | 49.16 % | 49.17 % | 48.92 % | 49.17 % | 48.93 % | 48.93 % | 48.93 % | 48.93 % | 48.93 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % |
| DIIs | 1.88 % | 1.88 % | 1.88 % | 1.69 % | 1.69 % | 1.69 % | 1.68 % | 1.68 % | 1.66 % | 1.65 % | 1.64 % | 1.64 % | 1.61 % | 1.60 % | 1.60 % | 1.60 % | 1.59 % | 1.60 % | 1.59 % | 1.59 % | 1.59 % | 1.59 % | 1.60 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 41.01 % | 40.99 % | 40.77 % | 41.56 % | 41.90 % | 41.81 % | 42.02 % | 42.08 % | 42.48 % | 43.07 % | 43.64 % | 43.60 % | 43.48 % | 43.49 % | 43.67 % | 44.02 % | 43.94 % | 43.89 % | 44.21 % | 44.55 % | 44.50 % | 44.52 % | 43.74 % |
| Others | 5.07 % | 5.09 % | 5.32 % | 5.47 % | 5.13 % | 5.23 % | 5.25 % | 5.19 % | 5.52 % | 5.13 % | 5.10 % | 5.14 % | 5.58 % | 5.60 % | 5.58 % | 5.22 % | 5.55 % | 5.35 % | 5.27 % | 4.93 % | 4.98 % | 4.96 % | 5.72 % |
| No of Share Holders | 0 | 1,993 | 2,301 | 3,681 | 3,674 | 3,573 | 3,620 | 3,678 | 3,901 | 4,521 | 4,609 | 4,625 | 4,627 | 4,635 | 6,315 | 7,507 | 6,840 | 7,511 | 8,018 | 8,121 | 7,976 | 7,906 | 8,120 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.6 | 1 | 0.65 | 0.66 | 0.7 | 0.7 | 0.7 | 0.7 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.42 | 0.24 | 0.56 | 0.14 | 0.08 | 0.09 | 0.1 | 0.1 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 08 Nov 2025 |  Quarterly Result Announcement | NA | 08 Nov 2025 | 1,723.30 | 1,551.30 |
| 18 Sept 2021 |  Dividend | ₹ 0.70 /share | 16 Sept 2021 | 415.70 | 454.45 |
| 22 Sept 2023 | Dividend | ₹ 0.70 /share | 22 Sept 2023 | 886.50 | 875.65 |
| 18 Jan 2024 |  Extraordinary General Meeting | NA | 18 Jan 2024 | 872.05 | 837.70 |
| 23 Sept 2024 | Dividend | ₹ 0.70 /share | 23 Sept 2024 | 981.65 | 767.60 |
| 30 Sept 2024 |  Annual General Meeting | NA | 30 Sept 2024 | 788.20 | 755.65 |
| 26 Oct 2024 | Quarterly Result Announcement | NA | 26 Oct 2024 | 774.70 | 726.85 |
| 04 Feb 2025 | Quarterly Result Announcement | NA | 04 Feb 2025 | 700.70 | 721.85 |
| 30 May 2025 | Quarterly Result Announcement | NA | 30 May 2025 | 724.55 | 771.00 |
| 30 Jul 2025 | Quarterly Result Announcement | NA | 30 Jul 2025 | 860.20 | 958.60 |
| 23 Sept 2025 | Dividend | ₹ 0.70 /share | 23 Sept 2025 | 771.65 | 1,216.75 |
| 30 Sept 2025 | Annual General Meeting | NA | 30 Sept 2025 | 1,211.90 | 1,309.50 |
| 22 Oct 2025 | Extraordinary General Meeting | NA | 22 Oct 2025 | 1,306.50 | 1,660.80 |
Announcements
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
2 hours ago
2 hours agoOutcome Of Board Meeting2 hours ago
2 hours agoBoard Meeting Outcome for Outcome Of Board Meeting.3 hours ago
3 hours agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation2 days ago
2 days agoBoard Meeting Intimation for Prior Intimation For The Board Meeting Of The Company To Be Held On Saturday 08Th November 2025Oct 28, 2025
Oct 28, 2025Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportOct 22, 2025
Oct 22, 2025Shareholder Meeting / Postal Ballot-Outcome of EGMOct 22, 2025
Oct 22, 2025Corrigendum I To The Notice Of Extraordinary General Meeting.Oct 17, 2025
Oct 17, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 13, 2025
Oct 13, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 11, 2025
Oct 11, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 09, 2025
Oct 09, 2025Announcement under Regulation 30 (LODR)-CessationOct 06, 2025
Oct 06, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 01, 2025
Oct 01, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportOct 01, 2025
Oct 01, 2025Intimation Of Record Date For The Purpose Of EOGM Of The Company.Sep 30, 2025
Sep 30, 2025Notice Of Book Closure For The Purpose Of Extra Ordinary General Meeting To Be Held On 22Nd October 2025.Sep 30, 2025
Sep 30, 2025Notice Convening Extra-Ordinary General Meeting (EOGM) Of Fredun Pharmaceuticals LimitedSep 30, 2025
Sep 30, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateSep 30, 2025
Sep 30, 2025Announcement under Regulation 30 (LODR)-Change in ManagementSep 30, 2025
Sep 30, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 30, 2025
Sep 30, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 27, 2025
Sep 27, 2025Closure of Trading WindowSep 26, 2025
Sep 26, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On 25Th September 2025 Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations)Sep 25, 2025
Sep 25, 2025Closure of Trading WindowSep 22, 2025
Sep 22, 2025Board Meeting Intimation for Prior Intimation Under Regulation 29 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (The SEBI LODR
Regulations)Sep 22, 2025
Sep 22, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 09, 2025
Sep 09, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 ("SEBI Listing Regulations").Sep 08, 2025
Sep 08, 2025Intimation Of Record Date For The Purpose Of Final Dividend For The Financial Year 2024-25Sep 08, 2025
Sep 08, 2025Notice Of Book Closure For The Purpose Of 38Th Annual General Meeting (AGM)Sep 08, 2025
Sep 08, 2025Submission Of The 38Th Annual Report Of Fredun Pharmaceuticals Limited For The Financial Year 2024-25.Sep 08, 2025
Sep 08, 2025Reg. 34 (1) Annual Report.Sep 08, 2025
Sep 08, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 03, 2025
Sep 03, 2025Announcement under Regulation 30 (LODR)-Meeting UpdatesSep 02, 2025
Sep 02, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 23, 2025
Aug 23, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 06, 2025
Aug 06, 2025Audio Recording Of The Q1 FY26 Earnings Conference CallAug 01, 2025
Aug 01, 2025Audio Recording Of The Q1 FY25 Earnings Conference CallAug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 31, 2025
Jul 31, 2025Appointment Of Non-Executive Independent Directors.Jul 30, 2025
Jul 30, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateJul 30, 2025
Jul 30, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 30, 2025
Jul 30, 2025Results For The Quarter Ended 30Th June 2025.Jul 30, 2025
Jul 30, 2025Board Meeting Outcome for Outcome Of Board MeetingJul 30, 2025
Jul 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 30, 2025
Jul 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 29, 2025
Jul 29, 2025Board Meeting Intimation for Prior Intimation For The Board Meeting Of The Company To Be Held On Wednesday 30 July 2025.Jul 14, 2025
Jul 14, 2025Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderJul 10, 2025
Jul 10, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 09, 2025
Jul 09, 2025Voluntary Disclosure - SEBI Adjudication Order Dated June 30 2025 (No Penalty Imposed)Jul 03, 2025
Jul 03, 2025Closure of Trading WindowJun 30, 2025
Jun 30, 2025Technical Indicators
RSI(14)
Neutral 54.69
ATR(14)
Less Volatile 83.31
STOCH(9,6)
Neutral 25.75
STOCH RSI(14)
Oversold 2.39
MACD(12,26)
Bearish -22.83
ADX(14)
Strong Trend 39.65
UO(9)
Bearish 47.05
ROC(12)
Downtrend And Accelerating -5.36
WillR(14)
Neutral -74.45
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
